Hypothalamic-pituitary-adrenal axis hypersensitivity to naloxone in opioid dependence: A case of naloxone-induced withdrawal

Metabolism: Clinical and Experimental

Volumn 46, Issue 2, 1997, Pages 130-134

  Culpepper Morgan, Joan A ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ENDORPHIN; CLONIDINE; DIAMORPHINE; HYDROCORTISONE; METHADONE; METYRAPONE; NALOXONE; OPIATE AGONIST; PERCOCET;

ADULT; ARTICLE; BACKACHE; CASE REPORT; CHRONIC PAIN; CONSTIPATION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; METHADONE TREATMENT; ORAL DRUG ADMINISTRATION; PARAPLEGIA; PRIORITY JOURNAL;

EID: 0031040817     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90289-4     Document Type: Article

References (32)

1. Himmelsbach CK: The morphine abstinence syndrome, its nature and treatment. Ann Intern Med 15:829-839, 1941
2. Wikler A, Fraser HF, Isbell H: W-allylnormorphine: Effects of single doses and precipitation of acute "abstinence syndromes" during addiction to morphine, methadone or heroin in man (post addicts). J Pharmacol Exp Ther 109:8-20, 1953
3. Jasinski DR, Martin WR, Haertzen CA: The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). J Pharmacol Exp Ther 157:420-426, 1967
4. Andrews HL, Himmelsbach CK: Relation of the intensity of the morphine abstinence syndrome to dosage. J Pharmacol Exp Ther 81:288-293, 1944
5. Heishman SJ, Stitzer ML, Bigelow GE, et al: Acute opioid physical dependence in postaddiet humans: Naloxone dose effects after brief morphine exposure. J Pharmacol Exp Ther 248:127-134, 1989
6. Suzuki T, Fukagawa Y, Yoshii T, et al: Modification of the effects of naloxone in morphine-dependent mice. Life Sci 45:1237-1246, 1989
7. Fudala PJ, Berkow LC, Fralich JL, et al: Use of naloxone in the assessment of opiate dependence. Life Sci 49:1809-1814, 1991
8. Volavka J, Cho D, Mallya A, et al: Naloxone increases ACTH and cortisol levels in man. N Engl J Med 300:1056-1057, 1979 (letter)
9. Cohen MR, Cohen RM, Pickar D, et al: High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. Arch Gen Psychiatry 40:613-619, 1983
10. Kreek MJ, Schneider BS, Raghunath J, et al: Prolonged (24 hour) infusion of the opioid antagonist naloxone does not significantly alter plasma levels of cortisol and ACTH in humans. Abstracts of the 7th International Congress of Endocrinology. Excerpta Medica, International Congress Series 652:845, 1984 (abstr)
11. Gold MS, Kleber HD: A rationale for opiate withdrawal symptomatology. Drug Alcohol Depend 4:419-424, 1979
12. Kreek MJ, Wardlaw SL, Friedman J, et al: Effects of chronic exogenous opioid administration on levels of one endogenous opioid (beta-endorphin) in man, in Simon E, Takagi H (eds): Advances in Endogenous and Exogenous Opioids. Tokyo, Japan, Kodansha, 1981, pp 364-366
13. Kreek MJ, Wardlaw SL, Hartman N, et al: Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci 33:409-411, 1983
14. Kreek MJ, Ragunath J, Plevy S, et al: ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5:277-278, 1984
15. Kosten TR, Kreek MJ, Ragunath J, et al: Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol Psychiatry 21:217-220, 1986
16. Kosten TR, Kreek MJ, Ragunath J, et al: A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci 39:55-59, 1986
17. Kosten TR, Morgan C, Kreek MJ: Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: Preliminary findings. Biol Psychiatry 32:523-528, 1992
18. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al: Treatment of opioid induced constipation with oral naloxone: A pilot study. Clin Pharmacol Ther 52:90-95, 1992
19. Hahn EF, Lahita R, Kreek MJ, et al: Naloxone radioimmunoassay: An improved antiserum. J Pharm Pharmacol 35:833-836, 1983
20. Albeck H, Woodfield S, Kreek MJ: Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. J Chromatogr 488:435-445, 1989
21. Yoburn BC, Cohen AH, Inturrisi CE: Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat. J Pharmacol Exp Ther 237:126-130, 1986
22. Kreek MJ, Ochshorn M, Ferdinands L, et al: Hypothalamicpituitary-adrenal axis (HPA) effects in humans of a new opioid antagonist nalmefene with mu and kappa receptor subtype activity. Abstracts of the 1987 INRC Conference Adelaide, Australia (abstr)
23. Ho WK, Wen HL, Ling N: Beta-endorphin-like immunoactivity in the plasma of heroin addicts and normal subjects. Neuropharmacology 19:117-120, 1980
24. Kreek MJ: Medical safety and side effects of methadone in tolerant individuals. JAMA 223:665-668, 1973
25. Kreek MJ: Medical complications in methadone patients. Ann NY Acad Sci 311:110-134, 1978
26. Mutti A, Folli D, Van der Venne MT, et al: Long-lasting impairment of neuroendocrine response to psychological stress in heroin addicts. Neurotoxicology 13:255-260, 1992
27. Vescovi PP, Pedrazzoni M, Gerra G, et al: Impaired ACTH and beta-endorphin response to sauna-induced hyperthermia in heroin addicts. Acta Endocrinol (Copenh) 121:484-488, 1989
28. Kennedy JA, Hartman N, Sbriglio R, et al: Metyrapone-induced withdrawal symptoms. Br J Addict 85:1133-1140, 1990
29. Kreek MJ: Medical safety, side effects and toxicity of methadone. Proceedings of the Fourth National Conference on Methadone Treatment NAPAN-NIMH. 1972, pp 171-174
30. Kreek MJ: Physiological implications of methadone treatment. Proceedings of the Fifth National Conference on Methadone Treatment NAPANII-NIMH. 1973, pp 85-91
31. Kreek MJ: Rationale for maintenance pharmacotherapy of opiate dependence, in O'Brien CP, Jaffe JH (eds): Addictive States. New York, NY, Raven, 1992, pp 205-230
32. Gold MS, Pottash AC, Sweeney DR, et al: Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. JAMA 243:343-346, 1980